Cannabis Clinical Trial
Official title:
Imaging the Effects of Intermittent Thetaburst Stimulation on Cannabis Self-Administration in Heavy Cannabis Users
The growing legalization of cannabis across the U.S. is associated with increases in cannabis use, and accordingly, an increase in the number of individuals with cannabis use problems, including cannabis use disorder (CUD). While there are several medications being investigated as treatment options for CUD, none have been FDA-approved, and there is limited efficacy of traditional behavioral therapy approaches for this population. Consequently, there is a pressing need for the development of new treatments, including approaches that specifically target the brain areas associated with problematic cannabis use behaviors. Elevated attention to drug cues is one of the primary causes of relapse in heavy cannabis users. Preliminary data suggests that transcranial magnetic stimulation (TMS), a non-invasive form of brain stimulation, may be a novel brain-based tool to decrease heightened attention to drug cues in people with CUD. Building on prior data, the primary goal of this study is to evaluate the feasibility and effectiveness of TMS as a tool to decrease attention to drug cues and reduce cannabis use. This study will evaluate whether 2 weeks of rTMS can be used to decrease attentional bias to cannabis cues and reduce cannabis use in heavy cannabis users. We will recruit sixty (60) non-treatment seeking, near-daily cannabis users to receive 10 daily sessions of either real or sham (aka placebo) rTMS over a 2-week period. Participants will live on a residential research unit for 3 weeks. During the residential stay, data on cannabis use (measured using standard human laboratory measures of choice to smoke cannabis) and relevant brain activity (measured using drug cue exposure fMRI tasks) will be collected before and after the course of 10 daily rTMS sessions. We will aim to show whether real rTMS treatment reduces brain response and attentional bias to cannabis cues and reduces cannabis use levels.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
| Completed |
NCT04199468 -
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
|
Phase 1 | |
| Completed |
NCT04587700 -
Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery
|
||
| Not yet recruiting |
NCT05899946 -
An Integrated Program to Promote Anti-cannabis Messages
|
N/A | |
| Active, not recruiting |
NCT02735954 -
Colorado Marijuana Users Health Cohort
|
||
| Completed |
NCT00842985 -
Dronabinol Interactions in Humans
|
N/A | |
| Completed |
NCT04124432 -
Behavioral Pharmacology of Cannabis and Nicotine
|
Phase 1 | |
| Active, not recruiting |
NCT04693884 -
Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise
|
Early Phase 1 | |
| Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
| Active, not recruiting |
NCT03560934 -
Tetrahydrocannabinol (THC) and Sleep
|
Early Phase 1 | |
| Recruiting |
NCT04704271 -
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
|
Phase 1 | |
| Withdrawn |
NCT03245658 -
The Effect of Cannabis in Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT04911127 -
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
|
Phase 1 | |
| Not yet recruiting |
NCT05999383 -
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
|
Phase 2 | |
| Recruiting |
NCT04429568 -
THC Crossover Study
|
N/A | |
| Completed |
NCT05554146 -
Pain Inflammation and Cannabis in HIV
|
N/A | |
| Not yet recruiting |
NCT05320367 -
A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users
|
Phase 1/Phase 2 | |
| Completed |
NCT02567344 -
Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving
|
N/A | |
| Terminated |
NCT03251326 -
Nabilone in Cannabis Users With PTSD
|
Phase 1/Phase 2 | |
| Completed |
NCT00176085 -
Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH
|
Phase 1 |